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ABSTRACT
In recent years a revival of interest has emerged in the health benefits of intermittent fasting
and long-term fasting, as well as of other related nutritional strategies. In addition to meal
size and composition a new focus on time and frequency of meals has gained attention. The
present review will investigate the effects of the main forms of fasting, activating the meta-
bolic switch from glucose to fat and ketones (G-to-K), starting 12–16 h after cessation or
strong reduction of food intake. During fasting the deactivation of mTOR regulated nutrient
signalling pathways and activation of the AMP protein kinase trigger cell repair and inhibit
anabolic processes. Clinical and animal studies have clearly indicated that modulating diet
and meal frequency, as well as application of fasting patterns, e.g. intermittent fasting, peri-
odic fasting, or long-term fasting are part of a new lifestyle approach leading to increased
life and health span, enhanced intrinsic defences against oxidative and metabolic stresses,
improved cognition, as well as a decrease in cardiovascular risk in both obese and non-obese
subjects. Finally, in order to better understand the mechanisms beyond fasting-related
changes, human studies as well as non-human models closer to human physiology may offer
useful clues.
KEY-MESSAGES
1. Biochemical changes during fasting are characterised by a glucose to ketone switch, lead-
ing to a rise of ketones, advantageously used for brain energy, with consequent
improved cognition.
2. Ketones reduce appetite and help maintain effective fasting.
3. Application of fasting patterns increases healthy life span and defences against oxidative
and metabolic stresses.
4. Today’s strategies for the use of therapeutic fasting are based on different protocols, gener-
ally relying on intermittent fasting, of different duration and calorie intake.
5. Long-term fasting, with durations between 5 and 21 days can be successfully repeated in
the course of a year.
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1. Introduction
In the evolution alternation of food availability and food
scarcity has been the consequence of seasonal cycles
with variations in sunlight exposure. Before humans
could efficiently conserve food, physiological and behav-
ioural adaptations to survive periods of food limitation,
have led to the development of the metabolic fasting
programmes. Storing food as fat in the adipose tissue
instead of carbohydrates or proteins, was a highly effi-
cient solution for humans and animals to cope with the
absence of food supply and it permitted to fuel pro-
longed periods of fasting [1,2]. In free living animals fast-
ing is coupled with migration, hibernation or huddling
to save energy. Bears [3] and ground squirrels [4] reduce
energy expenditure by hibernating and undergo pro-
longed fasting periods of months with no or little food
[5], whereas Emperor penguins fast during moulting and
breeding. During fasting, they can stand colder condi-
tions better than any other bird, while maintaining their
usual body temperature [6] thanks to the huddling
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behaviour [7,8]. Birds can undertake strenuous efforts
during long distance migration, while flying hundreds of
kilometres without food or drink [9].
Humans also had to adapt to natural cycles of food
scarcity for millions of years and only with the onset
of agriculture in the Neolithic era, more continuous
food supply became available. This culminated in
today’s technologies allowing humans in privileged
countries to have access to any type of food at any
time during the whole year. Extreme situations such
as famine [10], chronic malnutrition, hunger strikes or
long course of anorectic denial of food [11,12] have
also provided information about the human capacity
to cope with long periods of food shortage. In add-
ition to being a necessity for human survival, the abil-
ity to fast has been known in most religions as
traditionally ritualised periods lasting from hours to
weeks [13]. Religions used fasting empirically for its
effects on mind and body, as well as an important fac-
tor in community cohesion [14]. In medicine fasting
for 2–21 days or more was known for its numerous
therapeutic effects that led to multidisciplinary fasting
programmes [15], well-known in the public less in the
scientific community. Total fasting safely practiced for
31 days has been documented scientifically at the
beginning of the twentieth century [16]. Later on, in
the 1960s, as obesity started to be a medical issue on
a large scale, water fasting to treat morbid obesity
and co-morbidities emerged under the names of zero
calorie diet or total fasting [17]. The effects of this
type of fasting, lasting weeks or months, particularly
on obesity, have been extensively documented [18].
Nowadays a revival of the interest for fasting
emerges from a different perspective. Instead of
focussing only on weight loss in morbid obesity, the
new focus is on the effects of the main fasting regi-
mens, that activate the metabolic switch from liver-
derived glucose to adipose cell-derived ketones (G-to-
K) and its reversal K-to-G [19], on longevity, health
span expansion, multi-stress resistance and antioxidant
defence stimulation, improved performance and cellu-
lar regeneration in animal models and humans.
The present review investigates, in animal models
and humans, how application of several types of fast-
ing strategies, e.g. intermittent fasting, periodic fast-
ing, or long-term fasting could be part of a new
medical approach leading to improved healthy life
span and cognition, as well as to a decrement in car-
diovascular risk in both obese and non-obese subjects.
2. Fasting classification
Fasting is defined as the voluntary abstinence or
strong limitation of caloric ingestion for a limited
period of time, triggering the G-to-K switch and major
changes in the activity of signalling pathways. Further
effects also take place on refeeding when the K-to-G
switch occurs [19]. The big challenge when it comes
to classify fasting regimens is that duration has a very
different meaning if we consider animals, such as non-
obese mice, or humans. One day fasting brings the
mouse almost to starvation (ketones decrease and
protein catabolism increases), whereas a day in
humans is considered as intermittent fasting [20].
Table 1 summarises the main forms of fasting and
other restrictive diets. Calorie restriction (CR) refers to
a daily reduction by 15–40% of calorie intake without
malnutrition. Intermittent fasting (IF) refers to fasting
Table 1. Main forms of fasting and related diets.
Fasting and related diets Calorie intake Length
Calorie Restriction (CR) 70 % of normocaloric intake without
malnutrition (with possible variations)
Optional
Intermittent Fasting (IF)
Alternate Day Fasting (ADF) 0 kcal/alternating with ad libitum
(with possible variations)
Optional; alternation of fasting
and ad libitum food intake every other day
Time Restricted Feeding/Eating
(TRF/TRE) 16:8
Ad libitum with possible variations Optional; daily food intake is reduced to a time
window of 8 h (with possible variations)
Periodic Fasting (PF)
5:2 diet (5:2) 600 kcal/2 days per week/ad libitum Two consecutive or independent days
of calorie restriction every week
Long-term (LF) or prolonged Fasting
Buchinger Wilhelmi fasting 200–250 kcal/day >2 days to weeks according to baseline nutritional
and health status
Water-only fasting 0 kcal/day
Zero calorie diet 0 kcal/day Weeks to months. Weight-loss program practiced
between the 1960s and the 1970s
Very Low Calorie Diet (VLCD) 800–1000 kcal High protein formula weight-loss program with
reduced calorie intake for 6 -12 weeks
Fasting Mimicking Diet (FMD) 800–1100 kcal 5 days of calorie reduced low protein diet
(1 to 6 cycles per year)
Diets derived from fasting strategies.
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lengths between 16 and 48 h, alternated with usual
food intake. The most frequently studied IF procedure
is alternate day fasting (ADF) [21], whereby normal
food intake occurs on one day and restricted food the
next day. Time restricted eating/feeding (TRE/TRF)
is characterised by intake of food occurring within a
time window of 8–12 h per day or less [22]. Periodic
fasting (PF) describes cycles of fasting or calorie
restricted diets, i.e. 5:2 diet (5:2), referring to two days
per week, consecutive or not, in which food intake is
drastically reduced to approximately 600 kcal [23]. In
some classifications 5:2 is considered as IF. Periods of
fasting lasting from many days to weeks have some-
times been referred to as periodic and can be
repeated every year [24]. Other Authors referred to
them as long-term or prolonged fasting [25].
Considering that these adjectives do not take into
consideration differences in the baseline nutritional
status and between species, in the present review art-
icle we refer to long-term fasting (LF) as a food abstin-
ence from 2 to 21 days or more during which no or
minimal amounts of calories, up to 200–250 kcal/days
are given within appropriate schedules. LF has been
well documented in obese and non-obese subjects
[24] as well as in animals [7,26] and during the 1960s
in morbidly obese subjects [27]. Other regimens,
derived from fasting strategies, are the very-low-cal-
orie-diets (VLCD) [28], a hypocaloric formula diet pro-
viding 80–100 g of proteins and an average of
1000 kcal/days, designed to treat obesity and to avoid
a negative nitrogen balance. Furthermore, the fasting-
mimicking diet (FMD) [29,30] is a hypocaloric
(800–1100 kcal), low protein, ketogenic diet leading to
weight loss and to some of the effects of fasting. It is
worth mentioning that nutrient restricted normo-
caloric diets like the ketogenic diet (carbohydrate
restriction) and the protein or amino acid (methionine)
restricted diet [31] are being also inten-
sively evaluated.
3. Metabolic and cellular responses to fasting
3.1. The metabolic switch
The onset of fasting is characterised by the metabolic
switch, that defines the fuel switch occurring when an
organism commutes from the eating mode, including
generally around 50% carbohydrates, to the fasting
mode [19]. From 12 to 16 h after interrupting food
absorption, glucose levels drop, followed by a
decrease of insulin levels and at the same time of cir-
culating amino acid levels. The onset of the metabolic
switch depends on the liver glycogen content at the
beginning of the fast as well as on the composition of
the preceding meal, energy expenditure, and physical
activity [19]. Lipids in adipocytes (triacylglycerol and
diacylglycerol) are metabolised to free fatty acids
(FFAs) whose levels increase in fasting blood, to be
partly oxidised in most tissues, such as muscles, kid-
neys, heart and partly transformed in the liver to
ketones (b-hydroxybutyrate, acetoacetate and acetone)
[32]. Ketones are not only fuels, since they have also
signalling effects and regulate expression and activity
of transcription factors like the peroxisome prolifer-
ator-activated receptor c coactivator 1a (PGC-1a), sir-
tuins (SIRTs) [33], poly-adenosine diphosphate [ADP]-
ribose polymerase 1 (PARP1), and ADP ribosyl cyclase
[34], as well as fibroblast growth factor 21 [35,36] and
nicotinamide adenine dinucleotide (NADþ). A rise of
brain-derived neurotrophic factor (BDNF) in the central
nervous system (CNS) can enhance brain health [37].
Ketones are effectively oxidised by the fasting brain,
more reluctant than other tissues to renounce glucose
and metabolise FFAs [38]. The use of FFAs and
ketones as energy sources reduces the respiratory-
exchange ratio (RER), compared with the fed state,
indicating a greater metabolic efficiency of energy
production during weight loss leading to ketosis [25].
The decreased ATP/AMP ratio will activate AMP-acti-
vated protein kinase (AMPK) as well as create a mild
oxidative eustress [39] leading to the activation of
antioxidant and cytoprotective enzymes (i.e. super-
oxide dismutase, catalase, peroxidase, sulfiredoxin 1,
thioredoxin reductase 1, haem oxygenase-1, NAD(P)H
quinone oxidoreductase 1, glutamate-cysteine ligase,
glutathione S-transferases, and uridine 50- diphospho-
glucuronosyltransferases). During prolonged periods of
fasting, ketosis has been shown to reach a plateau
after 4 days, an effect that can last for several hours
or days, and to decrease when food is reintroduced
(Figure 1) [40].
The G-to-K switch is the key mechanism allowing to
spare proteins by reducing protein utilisation, as
reflected by the changes in nitrogen balance [41]. It is
regulated by inhibition of the mTOR (mechanistic/
mammalian target of Rapamycin) signalling pathway,
thus decreasing protein synthesis and enhancing
autophagy, that leads to the recycling of endogenous
proteins [25]. Relying on ketones for energy during
weight loss has the advantage of promoting retention
of lean mass; the same may not occur after plain CR
[42]. This conclusion was not supported in the most
extensive ADF studies to date [21]. At present, the
substantial benefit of fasting regimens on lean mass
retention needs to be reconsidered. While the
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adaptation to long-term fasting can promote lean
mass retention, this has not been definitely shown to
occur preferentially after IF rather than with CR [43]. It
should be noted that ketosis can be also obtained
with low energy and/or high fat diets [44].
Normocaloric strict high fat ketogenic diets are suc-
cessfully prescribed to epileptic children who do not
respond to drug treatments [45].
Switching from a carbohydrate to a lipid rich diet
has been successfully applied for weight reduction,
although, based on current evidence, low-CHO and
very-low-CHO diets do not appear to be clearly super-
ior to other dietary approaches [44]. Ketones serve as
an energy source, being metabolised to acetyl coen-
zyme A (AcCoA) entering the tricarboxylic acid cycle
generating adenosine triphosphate (ATP). They sustain
the function of muscle and brain cells during fasting
as well as extended periods of physical exertion [46].
Furthermore, ketosis leads to a fully compensated
acidosis, believed to be responsible for the characteris-
tic absence of hunger during fasting [47–49]. Absence
of hunger enhances compliance [24]. Blood glucose
stabilises at the lower normal level and will remain
stable during the whole fasting period, as long as fat
reserves can fuel metabolism and the protein pool
remains at the physiological limits [46].
Concomitantly, in a well-orchestrated manner, an
increase in the hormonal secretion of glucagon
(stimulation of glycogenolysis and gluconeogenesis)
[50], growth hormone (implicated in lipolysis) [51], cor-
tisol and adrenaline regulate the course of fasting [52].
Furthermore, along with a decrement in the adipokine
leptin and a rise in adiponectin [53], fasting signifi-
cantly reduces insulin like-growth factor (IGF)-1. Only
restrictions of 50% or more of normal daily energy
requirements can reduce IGF-1 levels [54]. Low levels
of IGF-1 reduce the intracellular mitogenic signalling
pathways, and lead mammalian cells to enter either a
non-dividing or a low-dividing state and invest energy
resources into cellular protection against various
insults (multi-stress resistance) [55].
Since during fasting very few or no exogenous pro-
teins or sugars enter the system, nutrient dependent
signalling pathways are shut down [mTOR and Ras-
adenylate cyclase (AC)-protein kinase A (PKA)], along
with the de-repression of transcription factors e.g.
SIRT, and forkhead box O1 (FOXO1), leading to the
many peculiar features of the fasting mode [37]. The
promotion of the multi-stress resistance is character-
ised by improved antioxidant defences, increased DNA
repair and diminished inflammation [56]. Moreover,
most of cardiovascular risk factors (waist circumfer-
ence, lipids, blood pressure and insulin resistance) are
improved by CR, IF or LF [57,58].
The fasting mode will be reversed as soon as a
mixed diet is reintroduced, triggering the K-to-G
Figure 1. Metabolic switch from carbohydrates to fatty acids and ketones induced by 10 days of fasting (daily energy intake of
about 250 kcal and multidisciplinary programme). A regression spline was fitted on individual acetoacetic values to show the varia-
tions in ketosis during the course of the study. T: transition to the fasting mode; RF: progressive reintroduction of food [40].
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switch: glucose and insulin levels increase, ketones
drop, mTOR is reactivated leading to increased protein
synthesis and mitochondrial biogenesis, as well as
decreased autophagy. Cell regeneration in multiple
systems occurs, with increased mesenchymal and pro-
genitor cells [29]. In this refeeding phase, specific
effects take place concomitant to cell growth and
plasticity, leading to functional tissue remodelling [25]
and offering a unique opportunity, in adult life, to
boost cellular and tissue regeneration [30]. In some
cases, an inappropriate pattern of food reintroduction
can lead to relapse of symptoms, as seen in the case
of LF prescription to treat polyarthritis [59].
3.2. Signalling pathways modulated by fasting
In the fasting mode, cellular and metabolic processes
are controlled by a complex network of transcriptional
regulators. Major regulators are SIRTs, nuclear factor
erythroid 2–related factor 2 (NRF2), FOXO1, nuclear
factor ‘kappa-light-chain-enhancer’ of activated b-cells
(NFkB), hypoxia inducible factor 1 a (HIF-1a), heat
shock factor (HSF-1). The decrease of the protein
responsive signalling pathway mTOR and of its down-
stream effector, the ribosomal protein S6 kinase b-1,
leads to global protein synthesis inhibition and recy-
cling of macromolecules by autophagy stimulation
[60]. In the brain, in addition to raised neuronal stress
resistance through bolstered mitochondrial function
there is an improvement in antioxidant defences, DNA
repair, and stimulation of BDNF production [61,62].
BDNF regulates hippocampal neurogenesis, dendrite
morphology and synapse plasticity, and increases pro-
duction of new neurons from neural stem cells [63].
The decrease in glucose levels in parallel to the rise in
ketones during fasting is associated with a decrement
in the glucose responsive Ras-AC-PKA pathway, impli-
cated in life span extension [64].
Other crucial consequences of fasting are the
decrease in insulin/IGF-1 signalling, leading to a reduc-
tion in anabolic processes and decrement in the ATP/
AMP ratio with consequent activation of AMPK. This
last step triggers repair and inhibition of the anabolic
processes [65] (Figure 2). Another mechanism associ-
ated to the fasting-induced activation of AMPK is
autophagy of muscle cells, a process preserving blood
glucose levels during LF. As a proof-of-concept, the
selective skeletal muscle depletion of AMPK resulted
in hypoglycaemia and hyperketosis, an effect not due
to an impairment in fatty acid oxidation, but instead
Figure 2. Representationof signalling pathways modulated fasting. The reduced levels of circulating amino acids and of IGF-1 con-
sequent to fasting repress the activity of mTOR and its downstream effector leading to an inhibition of global protein synthesis
and promote recycling of macromolecules by autophagy stimulation. There is a rise in the AMP-to-ATP ratio leading to the activa-
tion of AMPK. SIRT1-driven deacetylation of PGC-1a and FOXO1 transcription factors provides a mechanism by which mitochon-
drial and lipid oxidation genes can be dynamically controlled in response to energy demand. AMPK: AMP-activated protein kinase;
FOXO1: forkhead box O1; IGF: insulin-like growth factor; NADþ: nicotinamide adenine dinucleotide; PGC-1a: peroxisome prolifera-
tor–activated receptor c coactivator 1a; mTOR: mammalian target of Rapamycin; SIRT: sirtuin.
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to a reduction in autophagy of muscle cells, leading
to reduced circulating levels of alanine, an essential
amino acid required for gluconeogenesis [66].
Among the many activated transcriptional regula-
tors quoted above, hepatic SIRT1 protein levels are
raised during fasting and reduced with refeeding [67].
SIRT1-driven deacetylation of PGC-1a [68] and the
increased FOXO1 transcription factor provides a mech-
anism by which mitochondrial and lipid oxidation
genes can be dynamically controlled in response to
energy demand [69]. A specific liver knock down of
SIRT1 results in a decreased fasting-dependent down-
regulation of the lipogenic gene expression (SREBP-
1c), suggesting this mechanism for the regulation by
SIRT1 of multiple SREBP-1 target genes [70]. SIRT1 sup-
presses glucose production by inhibiting the CREB
regulated transcription coactivator 2 (CRTC2)-mediated
gluconeogenesis, activated during the G-to-K switch
[71]. Similar to SIRT1, the mitochondrial deacetylase
SIRT3 regulates metabolic homeostasis during fasting
and CR [72]. SIRT3 is critical for fatty acid oxidation
and ketogenesis during fasting, by regulating the
deacetylation state and the activity of mitochondrial
enzymes involved in the metabolic switch. Having
thus a major role in liver ketogenesis, mice lacking
SIRT3 display lower plasma b-hydroxybutyrate levels
during fasting [72].
4. Evidence from experimental animals
The life and health span extension produced by CR
has been an area of interest since the late 1970s [73].
Compared to mice assigned to an ad libitum regimen,
30% CR and TRF (single-meal feeding) enhanced lon-
gevity, regardless of diet composition and showed
improvements in morbidity and mortality [74].
Prevention of age-related declines, as evaluated by
tests of motor coordination (rotarod) and learning
(complex maze) took place in mice exposed to a 50%
CR regimen. Increased locomotor activity in a run-
wheel cage, regardless of age was observed, without
effects on exploratory activity in a novel arena [75].
This type of functional improvement has been related
to anatomical changes, such as a rise in synapse
numbers and stimulation of mitochondrial biogenesis,
correlated with increased BDNF levels [76]. 3-hydroxy-
butyrate may also mediate adaptive responses of neu-
rons to fasting, exercise and ketogenic diets [77]. In
mice, hippocampus dependent spatial learning and
memory deficit improve upon a daily TRF with amelio-
rated behavioural changes, in particular anxiety-like
behaviours. These improvements, found in old mice,
may rely on the enhanced cerebral blood flow and
blood-brain barrier function, similar to that seen in
young mice at 5–6months of age following CR [78].
Relative to TRE, the study of mechanisms leading to
changes in the molecular circadian clock genes, acti-
vated or deactivated according to light and diet, has
opened new horizons [65]. These circadian rhythms,
displaying oscillations over a period of 24 h, are evolu-
tionarily conserved and driven by the need to syn-
chronise biological activity with the ever-changing,
but predictable, environment of the rotating Earth. In
mammals, feeding behaviour is cyclic with periods of
fasting separating feeding bouts, leading the organism
to switch from nutrient storage during feeding periods
to the use of stored nutrients during fasting [22].
Studies on the effects of a disruption of metabolic cir-
cadian cycles, showed that under TRF, in which mice
are fed an equivalent amount of food as the ad libi-
tum cohort but for a defined period of 8 h, mice were
protected against obesity, hyperinsulinemia, hepatic
steatosis, and inflammation [60]. Compared to rats fed
ad libitum, those exposed to ADF present lower rest-
ing heart rate and blood pressure (BP), this last
remaining lower after exposure to immobilisation and
swim stressors [79], and equal to or greater than that
previously obtained with exercise training regimens in
rats [80].
Other Authors confirmed that TRF regimens, com-
pared to prolonged ad libitum feeding are associated
to an improved hemodynamic profile, i.e. reduced
heart rate and systolic and diastolic BP. TRF decreases
the sympathetic autonomic nervous system activity
and raises the parasympathetic or vagal tone [81].
Another TRF regimen of 4 h-feeding/day in mice
restored the expression of clock genes, leading to
reduced body weight, cholesterolaemia, tumour necro-
sis factor-a and improved insulin sensitivity [82]. These
findings suggest that TRF can normalise the expres-
sion of genes involved in fatty acid metabolism, b-oxi-
dation, PPARc and antioxidant defences in the liver.
The correlation between clock genes and TRF has
recently been documented by a study in mice lacking
a circadian clock. When these are provided with access
to high energy food ad libitum they gain weight
quickly, but when subjected to a TRF regimen (10 h),
they are protected from the weight gain and meta-
bolic diseases driven by a high-energy diet [83].
Prolonged ADF can upregulate the hemo-oxygen-
ase1 and glucose-regulated protein 7B, both reduced
by aging, in the cerebral cortex and striatum. These
cytoprotective proteins against metabolic and oxida-
tive stresses [84] rise after ADF and appear to sustain
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expression/responsivity of genes involved in adaptive
neuroplasticity and cognition [85]. Similarly, in the
case of animal models of neurologic disorders, includ-
ing epilepsy, Alzheimer, Parkinson disease and stroke,
application of an IF regimen (feeding for 8 h/day)
appears to protect against the neurological damage in
ischaemic stroke, with circulating leptin as a possible
mediator [86]. Mice maintained on a chronic IF for
11months exhibited a superior cognitive ability in the
Barnes maze test of spatial memory [53]. This type of
positive response also occurred after a late-onset
short-term IF dietary restriction for three months in
old rats (animals fasted overnight) [87].
A better cognitive performance was also reported
when mice were fed cycles of FMD lasting 4 days, fol-
lowed by a standard ad libitum diet. Compared to
control mice, FMD resulted in a rise in life span, i.e. up
to 28.3 vs 25.5months. Bi-monthly application of this
dietary approach reduced visceral fat, cancer incidence
and skin lesions, rejuvenated the immune system, and
retarded bone mineral density loss; when applied later
in life, there was improved cognitive performance [29].
5. Therapeutic fasting: clinical impact in
contemporary medicine
Modulating diet and meal frequency as well as several
patterns of fasting can represent a new paradigm in
today’s medical approaches. As recently highlighted
by de Cabo and Mattson, Homo sapiens has adapted
to fasting in ways that enable the organism to tolerate
or overcome challenges and then restore homeostasis
[25]. An increasing number of physiological effects
linked to IF can be applied also to LF, at least in the
initial phase, leading to (i) weight loss and metabolic
reset, (ii) increased insulin sensitivity, (iii) reduction in
inflammation and oxidative damage to proteins, lipids
and DNA, as well as (iv) enhanced immune system
function [88]. All these mechanisms are definitely of
value in the management of obese as well as non-
obese subjects.
5.1. LF – a general overview
Whereas the metabolic switch and the changes in sig-
nalling pathways above described also apply at the
beginning of LF, the question is whether these effects
persist, decrease or increase in the course of LF.
Evidently, it will depend on the duration of fasting,
the individual profile including age, nutritional and
health status, as well as personal inclination for the
procedure [89]. One of the first detailed scientific
observations of a non-obese voluntary subject on total
fasting ended safely after 31 days [16]. Other case
reports of persons fasting during several weeks were
published and brought stupefaction in the medical
community and the public. Many Authors have
stressed the well-being, the absence of hunger and
lifted mood reported by fasting obese and non-obese
subjects [90]. The human capacity to live without
energy intake for periods of almost 40 days has been
often reported in non-obese subjects during hunger
strikes [91].
A medically supervised practice of LF has a long
tradition in Europe and in particular in Germany. The
safety of this programme has been recently docu-
mented in large cohort studies [15,24]. This type of LF,
generally lasting from 4 to 21 days, has been studied
in various clinical conditions: chronic inflammatory dis-
orders [92,93] and rheumatoid arthritis [59,94], hyper-
tension [95], irritable bowel syndrome [96], insulin
resistance, type 2 diabetes and metabolic syndrome
[97,98], fibromyalgia [99], breast and ovarian cancer
[100], osteoarthritis [101], obesity [102], and fatty liver
[103]. Furthermore, MRI evaluation documented sig-
nificant changes in body composition after 14 days of
fasting [104].
LF was first documented in morbidly obese subjects
in numerous publications from 1959 [90] to 1975 [41],
reporting fasting periods from several days up to 249
or, in an extreme case report, to 382 days [105,106],
called “zero calorie diets” or “total fasting,” sometimes
with administration of multi-vitamins and potassium
supplements. The main concern at that time was to
elucidate how humans could fast that long, having a
limited possibility to break down their protein pool
and at the same time the need to provide their CNS
with energy: the daily calorie needs of the brain in the
eating phases are 400–570 kcal delivered by 100–145 g
glucose [46]. If these needs have to be met by gluco-
neogenesis, since fatty acids cannot be transformed
into glucose, this would mean catabolizing 200 g of
proteins daily. Since the human protein body pool is
roughly 6000–8000 g [107] and cannot drop more
than 1/3 [108], this would reduce the ability to fast for
long periods. In fasting subjects, after depletion of the
glycogen stores, a rapid decrease in carbohydrate oxi-
dation and protein catabolism takes place.
Measurement of urinary nitrogen excretion allowed to
determine protein utilisation. Whereas at the begin-
ning of fasting 35 g of nitrogen were excreted per
day, these values tended to fall to 2–4 g/day (12–25 g
protein/d) after 4weeks [109]. The brain was increas-
ingly fed with ketone bodies, especially
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b-hydroxybutyrate, keeping it alert in order to stay
able to face challenges [46,110].
The protein sparing mechanism is induced by the
metabolic switch of G-to-K, as described by Longo &
Mattson decades later [111]. Cahill demonstrated the
fuel change occurring in the brain after 38–41 days of
fasting [46]. The brain system metabolises only 30% of
glucose supplied by the glycerol molecule, liberated
after cleavage of three fatty acids from triglycerides by
lipoprotein lipase. Altogether, during total fasting, up
to 41 days, 86 g/24h glucose is produced: half of this
comes from blood cells, producing lactate and pyru-
vate through glycolysis, then resynthesized to glucose
in the liver. The other half comes from glycerol and
gluconeogenesis, taking place first in the liver and
then in the kidneys from amino acids, respectively ala-
nine and glutamine [112]. This shift produces ammo-
nium to titrate ketone bodies [113].
Three phases have been described in the course of
LF in animals, such as the Emperor penguin, that
undergo yearly, during 35 years (average life span)
fasting periods lasting several weeks until exhaustion
of energy reserves [114]. An initial phase 1, when the
metabolic switch occurs, is followed by a phase of
protein sparing called phase 2, lasting several days to
weeks. Phase 3 finally starts when fat and protein
reserves have reached a threshold, forcing animals to
refeed [115]. Phase 3 is characterised by a high cata-
bolic activity, as well as adrenergic stimulation and
underlines the urgent need to replenish energy stores.
Nevertheless, the process is fully reversible. In humans
these three phases seem to exist in a similar way.
Under physiological condition of therapeutic fasting,
phase 3 is not reached. Phase 3 has been described in
anorexia [11].
The zero-calorie diet, where only non-caloric bever-
ages are permitted, was relatively well tolerated for
several weeks or even months, even though obese
persons were often without exercise, psychological
support or nutritional education to prevent relapses.
Pioneers of this type of fasting to treat obesity made
even the recommendation – surprising for our con-
temporaries – that obese subjects should not fast lon-
ger than 100 days without nitrogen balance
monitoring [116]. The publication of a single case of
death caused by acute intractable heart arrest hap-
pened on the seventh refeeding day in a 20-year-old
woman [117]. She had been on a 30week zero calorie
diet, reducing her weight from 118 to 60 kg. By simple
calculation this would mean a protein utilisation of
4000 g, i.e. more than 50% of her protein pool, this
being the most plausible death aetiology. At autopsy
a decrease of myofibril diameter in the heart with
gross fragmentation was diagnosed. Isolated cases of
death by very prolonged zero calorie diet periods of
several weeks or months in morbidly obese had not
always such a clear aetiology; other possible causes of
death include factors such as potassium or vitamin
deficiencies, imperfect patient selection or compliance,
associated medications or pre-existing dis-
ease [118–120].
For several years, zero calorie diets were followed
by a medical team in hospital wards. Despite the poly-
morbidity of the patients, the procedure seemed to be
safe for periods of 60–100 days. Because of the long
duration, the costs for hospitalisation were considered
as too elevated and, as a consequence, people started
total fasting on their own. Furthermore, obese subjects
could also buy protein supplemented diet formulas in
supermarkets, without any supervision. One of these
products consisting of a liquid based hydrolysate of
collagen proteins, the so called “liquid protein diet”
(LPD) was linked to deaths from cardiac arrest in 32
out of 44 casualties [118]. Again, the histological diag-
nosis was myofibrillar gross fragmentation but, unlike
the first documented case, the subjects were still
obese. The poor protein quality of LPD might have
played an accelerating role in protein pool depletion
or else in depletion of specific amino acids.
After these events, the depletion of the protein
pool was incriminated and this led to a strict regula-
tion of what has been called VLCD (very low calorie
diet), a hypocaloric formula providing 80–100 g good
quality protein/day. The main objective was to avoid a
negative nitrogen balance measured by 24 h urinary
excretion [109]. VLCD were prescribed to last not
more than 6weeks. By reflection, this reduction of the
fasting period alone could have sufficed to reduce risk
drastically. Protein formulas provided a market
allowing to design ambulatory multidisciplinary pro-
grammes. The need to provide proteins was not ques-
tioned any more until today.
5.1.1. Impact of LF on health and well-being
The practice of LF has reached a wide network of util-
isation in Europe. Among 1422 subjects who followed
fasting periods (daily calorie intake of 200–250 kcal
accompanied by a multidisciplinary lifestyle pro-
gramme) lasting between 4 and 21 days, there were
significant reductions in body weight, between
3.2 ± 0.0 kg after 5 and 8.6 ± 0.3 kg after 20 days of fast-
ing, as well as in abdominal circumference, i.e.
between 4.6 ± 0.1 cm and 8.8 ± 0.8 cm, respectively. BP
decreased for the whole group from 131.6 ± 0.7 to
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120.7 ± 0.4 for systolic BP and from 83.7 ± 0.4 to
77.9 ± 0.3 for diastolic BP [24]. A reduction of total
cholesterol (0.4 ± 0.0mmol/L), triglycerides
(0.4 ± 0.0mmol/L), glucose (0.7 ± 0.1mmol/L) and
HbA1c (1.2 ± 0.1mmol/mol) was reported. The
absence of hunger feeling, documented in 93.2% of
the subjects and an increase of emotional and physical
well-being was documented. None of the subjects
dropped out of the fasting procedure. Adverse effects,
e.g. cardiac arrhythmia, were reported in less than 1%
and mild symptoms like headache and fatigue
occurred rarely and mainly in the first days. In another
study on 174 hypertensive patients, who underwent a
water-only fasting programme (approximately 10 days),
90% of the subjects achieved a reduction of BP to
below 140/90mm Hg [121].
An improved fatty liver index (FLI), a surrogate
marker of non-alcoholic fatty liver disease (NAFLD),
has been recently described after LF in subjects with
and without type 2 diabetes [103]. In a series of 697
subjects, out of whom 264 had a baseline FLI > 60
(threshold for fatty liver), a LF of 8.5 ± 4.0 days was car-
ried out, providing 250 kcal/day and large quantities of
water. FLI decreased in the whole cohort significantly
(14.02 ± 11.67), the largest benefit being noted in
diabetics (19.15 ± 11.0). BMI decreased by 1.51 ± 0.82
kg/m2, 50% of the subjects losing more than 5% body
weight. Improvement of FLI was significantly corre-
lated with the number of fasting days and with the
magnitude of BMI reduction [103].
5.1.2. LF and microbiota
The contribution of gut microbiota to human diseases
is being intensively studied, such as in the case of
inflammatory bowel disease, gastric ulcers, NAFLD,
obesity, metabolic syndrome as well as associated
neurologic disorders [122]. This has led to a detailed
evaluation of dietary changes since gut microbiota
relies, almost entirely, on host diet composition and
food processing capacity, to obtain the metabolic sub-
strates needed to cover its energy requirements
(150–450 kcal/d, 628–1883 kJ/d). Thus, it seems inevit-
able that periods of fasting may have an impact on
gut microbiota [123]. Ten days of fasting in 15 healthy
men led to a decrease in abundance of
Lachnospiraceae and Ruminococcaceae, as shown by
faecal 16S rRNA gene amplicon sequencing, with a
concomitant rise in Bacteroidetes and Proteobacteria
(Escherichia coli and Bilophila wadsworthia). These
changes were associated with an increase in faecal
branched-chain amino acids (BCAA) by 18%, possibly
coming from host-derived compounds such as
desquamated cells attacked by the microbiota. The
effects were reversed three months after fasting [40].
In obese women on a VLCD (800 kcal/day) for 4weeks
major consistent changes in dominant faecal bacterial
communities were reported [124].
A potential benefit of microbiomal changes after
fasting is the amelioration of the altered gut micro-
biome in relapsing-remitting multiple sclerosis [125].
Since CR has a clear anti-inflammatory potential and
chronic CR has been shown to attenuate autoimmune
encephalomyelitis [126], therapeutic fasting may be of
value in the management of CNS autoimmunity. At
present, experimental data have shown raised gut
bacterial richness after IF, with enhanced anti-oxidative
microbial metabolic pathways [127]. In the same
report the Authors describe similar microbiomal
changes following IF in a series of MS patients. There
are at present only plans to test PF. A controlled clin-
ical trial on LF is ongoing in metabolic syndrome
(NCT02099968), as well as on IF in relapsing-remitting
multiple sclerosis (NTC03539094).
5.2. Impact of CR and IF on cardiometabolic risk
factors in non-obese and obese subjects
The CALERIE (Comprehensive Assessment of the Long-
Term Effects of Reducing Intake of Energy) study
[128,129], enrolled participants with BMI between 22
and 28 kg/m2, proposing a 25% CR throughout a 2-
year period with a control group staying on their cur-
rent diet. CR significantly improved general health and
mood [130]. Weight, body fat, fat mass, and fat free
mass as well as cardiometabolic risk factors, i.e. lipids,
BP, C-reactive protein, and insulin sensitivity index
were significantly reduced compared to controls
[131–133]. Concerning obese subjects, the TEMPO
(Type of Energy Manipulation for Promoting Optimum
Metabolic Health and Body Composition in Obesity)
trial compared the long-term impact of a 25–35% CR
during 12months vs a 65–75% CR during 4months
followed by 8months of a more moderate energy
restriction. Both interventions had a prescribed protein
intake of 1.0 g/kg of baseline body weight per day.
Among the 101 recruited postmenopausal women,
those on the 65–75% CR lost more abdominal sub-
cutaneous and visceral adipose tissue, but they also
lost more whole body and thigh muscle lean mass,
proportional to the total weight loss. Moreover, partic-
ipants allocated to the severe group lost more total
hip mineral density. Overall, although these changes
were not related to differences in muscle strength
[134], prudence should be exerted as in any
ANNALS OF MEDICINE 9
manipulation of food intake in men or postmeno-
pausal women with sarcopenia or osteoporosis.
Relative to the ADF approach, this was proven to
be acceptable and effective (weight loss being 2.5%
and fat mass 4%) in non-obese subjects who under-
went fasting every other day for 22 days [135]. Most
recently, following a similar approach, Stekovic et al.
[136] investigated the direct effects of ADF during
4weeks in a series of normal weight individuals, lead-
ing to an average 37% reduction of the daily calorie
intake. Improved sense of well-being and improve-
ment of cardiovascular risk markers, in particular trigly-
cerides and LDL-cholesterol, with reduced trunk fat,
fat-to-lean ratio and of the inflammatory marker sol-
uble inter-cellular adhesion molecule-1 (sICAM) were
detected. An increase of b-hydroxybutyrate occurred
even in non-fasting days. Interestingly, the pro-aging
amino acid methionine was periodically depleted.
Another study compared the effects of CR vs ADF
enrolling 100 participants. These were randomised to
adhere for 1 year (6-month intervention followed by
6-month weight maintenance) to one of the following
regimens: (i) ADF (25% of energy needs on fasting
days and 125% on alternating feast days), and (ii) 75%
CR. Compared to the control group, no differences
between interventions were found either in weight
loss, 6.0% vs 5.3%, respectively or in systolic and
diastolic BPs, heart rate, triglycerides, fasting glucose,
C-reactive protein. Overall, the Authors concluded that
ADF is not superior to a CR approach and leads to a
higher rate of dropouts, i.e. 38% (13/34) vs 29% (10/
35), respectively [21]. It should be recalled that, as
elsewhere reviewed [19], IF generally results in signifi-
cant reductions in body weight and fat mass, the
magnitude of weight losses being quite large (
5.0 kg), except in trials less than 8weeks in duration.
In obese individuals (BMI  30 kg/m2), Catenacci
and colleagues compared ADF with CR during an
8week-intervention [137]. Neither weight loss nor
body composition, lipids and insulin sensitivity differed
between groups. After 24weeks of unsupervised fol-
low-up aimed at assessing weight regain, there were
no significant differences but changes in percent fat
mass and lean mass were more favourable in the ADF
group. Patients exercising more during the follow-up
had a better weight maintenance [137], an often
documented observation [138].
As above described, IF regimens have been shown
to reduce global fat mass and visceral fat, both linked
to a reduced risk of diabetes development [139] and
thus of cardiovascular outcomes [140]. In overweight or
obese patients with type 2 diabetes, 12weeks of the
5:2 diet (400–600Kcal/two days/week) did not differ
from continuous energy restriction (1200–1400 kcal/day)
in reducing glycated haemoglobin (0.7%). The 5:2
group showed an increased tendency to hypoglycaemia
despite medication reduction [141].
Application of ADF in obese subjects for 10weeks
reduced total cholesterol, LDL-cholesterol and trigly-
cerides with a switch towards a rise of LDL size by 5%
and a reduction of small LDL by 9% [142]. A similar
lipid improvement was found in obese patients follow-
ing a modified protocol of ADF with an overall 25%
reduction of energy needs. Furthermore, a decrement
in systolic BP as well as in C-reactive protein were also
found [58,143]. In overweight women, daily energy
restriction (600–650 kcal/days for 2 days/week) vs
intermittent energy and carbohydrate restriction was
superior in improving body fat reduction and insulin
sensitivity [144].
Finally, in a very recent trial, enrolling 19 metabolic
syndrome patients, application of TRE, i.e. a reduction
of daily eating window from  14 h to a self-selected
10 h window over 12weeks, led to healthier body
composition, lowered BP, and decreased levels of car-
diovascular risk associated lipids [145]. Moreover, TRE
led to a modest, but not significant increase in sleep
duration with no impact on sleep efficiency and a
trend towards a reduction in physical activity.
Conclusions
While clinical studies on fasting have generally shown
positive effects on health and possibly on life span,
documenting benefits and challenges of long-term
fasting still needs further studies. The question
whether repeated cycles of fasting, as it happens
spontaneously in animals, can enhance benefits, is still
awaiting a definite answer. After having been rated, in
the 1960s, as a successful strategy to treat obesity and
comorbidities, additional benefits of fasting other than
weight loss have been uncovered. Among others are
improvements in glucose regulation, BP and heart
rate, as well as abdominal fat loss. The key point in
the clinical approach of fasting will be dependent
upon acceptance and compliance, as well as on safety.
These issues are linked to the emotional and physical
well-being, the absence of hunger and the presence
of professional guidance. TRE and IF can well fit in
everyday life and may be possibly adopted as a life-
long eating behaviour. Long-term fasting, in fact,
requires specialised settings, possibly away from the
usual environment.
10 F. WILHELMI DE TOLEDO ET AL.
An emerging aspect, in the planning of the fasting
strategy, is the after-fast period, when food is reintro-
duced. When the fasting process is reversed, symptom
relapses can occur in the absence of specific nutri-
tional guidelines. This may partially reduce the numer-
ous health benefits of fasting. The individual limits of
this procedure need to be carefully analysed and, simi-
lar to any manipulation of food intake, prudence is
necessary, particularly in older subjects and in the
case of low BMI, sarcopenia or eating disorders.
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